Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00504270 · ClinicalTrials.gov registry record · Phase 2

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

A Phase 2 study of Psoriasis, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 2
Development phase
66
Enrollment target
15
Study locations

NCT00504270: Completed Phase 2 study of Psoriasis, sponsored by Hoffmann-La Roche.

NCT00504270 is a Phase 2 study of Psoriasis that has completed, run by Hoffmann-La Roche. The registered enrollment target is 66 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (86% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00504270, a Phase 2 study of Psoriasis, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 2
Development phase
66 participants
Enrollment target
15
Study locations

Study Summary

This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis. Patients will be randomized to one of 3 treatment groups to receive once daily oral treatment with a)R3421 20mg, b)R3421 120mg, or c)placebo. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.

Conditions Studied

Psoriasis

Interventions

  • DRUG Placebo
  • DRUG RG3421 120mg
  • DRUG RG3421 20mg

Study Locations (15)

New York

  • - New York
  • - New York
  • - Stony Brook

Texas

  • - Galveston
  • - San Antonio
  • - Webster

Arkansas

  • - Hot Springs
  • - Little Rock

California

  • - Santa Monica

Georgia

  • - Alpharetta

New Jersey

  • - East Windsor

New Mexico

  • - Albuquerque

North Carolina

  • - Winston-Salem

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2007-07
Est. Completion 2009-09
Phase Phase 2
Hoffmann-La Roche

909 total trials

What the finished NCT00504270 record still lists

NCT00504270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00504270 lists 15 locations in 10 states (New York, Texas, Arkansas).

Frequently Asked Questions

What is clinical trial NCT00504270 about?

NCT00504270 is a clinical study titled "A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.". This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis. Patients will be randomized to one of 3 treatment groups to receive once daily oral treatment with a)R3421 20mg, b)R3421 120mg, or c)placebo. The anticipated t...

What is the current status of trial NCT00504270?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2007-07. Estimated completion is 2009-09.

What conditions does trial NCT00504270 study?

This clinical trial studies the following conditions: Psoriasis.

What interventions are being tested in trial NCT00504270?

The interventions under investigation include: Placebo (DRUG), RG3421 120mg (DRUG), RG3421 20mg (DRUG).

Who is sponsoring clinical trial NCT00504270?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00504270 being conducted?

This trial has 15 study locations across Arkansas, California, Georgia, New Jersey, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00504270's enrollment target sits among peer trials

66 66th of 125 higher than 60 of 125 other Psoriasis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02584244 · 66 participants · Phase 1

    Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

  • NCT03067051 · 66 participants · Phase 1

    Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

  • NCT03754725 · 66 participants · Phase 1

    Ferritin and Iron Burden in SAH sIRB

  • NCT03875378 · 66 participants · Phase 2

    Transdermal Estrogen in Women With Anorexia Nervosa

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00504270, the US trial registry maintained by the National Library of Medicine. NCT00504270 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.